Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
Aldactone
Generic name / active ingredient
spironolactone
Dosage-form class
Oral film-coated tablets: 25 mg, 50 mg and 100 mg (as listed in the current U.S. label)
Route
Oral
Record reviewed
2026-09-04

Copy from the pack in hand

Source-linked reading points

  • Check ALDACTONE, spironolactone, 25, 50 or 100 mg per tablet, oral-tablet form, actual NDC and target market together. Milligrams are the labelled amount in an exact tablet, not a web rule for personal tablet count, alternate-day use or replacing one pack with another.
  • The label includes warnings about hyperkalaemia, worsening renal function, hypotension and electrolyte abnormalities, and flags potassium supplements, high-potassium foods and salt substitutes for review. These do not let a website decide whether an individual should use or avoid a product; take the packs, supplements, OTC products and complete medicine list to a pharmacist or clinician.
  • “Diuretic”, “aldosterone antagonist” and “potassium-sparing” are class clues; they do not permit self-combining, alternating or replacing ALDACTONE with another diuretic, blood-pressure medicine, heart-failure medicine, potassium product or herb. Strength, dosage form, target-market label, prior reactions and test results all need review together.
  • The label identifies other potassium-raising products, NSAIDs (common in pain or fever medicines) and lithium as co-medication clues requiring professional review. NSAIDs may reduce diuretic, natriuretic or antihypertensive effects, while diuretics may reduce lithium clearance and increase lithium-toxicity risk. When these names appear, the complete medicine list, kidney function and relevant tests need review rather than self-separating timing, stopping or changing an amount.

Reviewed presentation examples — compare every field

  • 25 mg per tablet; 100-tablet bottleNDC 0025-1001-31
  • 50 mg per tablet; 100-tablet bottleNDC 0025-1041-31
  • 100 mg per tablet; 100-tablet bottleNDC 0025-1031-31

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-09-04
Source record
3 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image